About (Lyso)-N-acylphosphatidylethanolamine lipase
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4) is a protein
from Homo sapiens identified by UniProt accession
Q8TB40, 342 residues long.
MolForge cross-references it against 0 known binders and
27 disease associations.
Target properties
| Protein name | (Lyso)-N-acylphosphatidylethanolamine lipase |
|---|
| UniProt accession | Q8TB40 |
|---|
| Gene | ABHD4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 342 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (27)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.18
- neurofibrillary tangles measurement · score 0.09
- Palmar Fibromatosis · score 0.08
- periodontal measurement · score 0.07
- monocyte count · score 0.07
- Platelet-activating factor acetylhydrolase deficiency · score 0.05
- narcolepsy-cataplexy syndrome · score 0.04
- adolescent idiopathic scoliosis · score 0.02
- Obesity · score 0.02
- angina unstable · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8TB40-F1 | alphafold | PREDICTED | 88.22 | — |
Amino-acid sequence (342 residues)
MADDLEQQSQ GWLSSWLPTW RPTSMSQLKN VEARILQCLQ NKFLARYVSL PNQNKIWTVT VSPEQNDRTP LVMVHGFGGG VGLWILNMDS LSARRTLHTF DLLGFGRSSR PAFPRDPEGA EDEFVTSIET WRETMGIPSM ILLGHSLGGF LATSYSIKYP DRVKHLILVD PWGFPLRPTN PSEIRAPPAW VKAVASVLGR SNPLAVLRVA GPWGPGLVQR FRPDFKRKFA DFFEDDTISE YIYHCNAQNP SGETAFKAMM ESFGWARRPM LERIHLIRKD VPITMIYGSD TWIDTSTGKK VKMQRPDSYV RDMEIKGASH HVYADQPHIF NAVVEEICDS VD
Explore (Lyso)-N-acylphosphatidylethanolamine lipase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets